Evidence map›Paper›PMID 27709332›Full record

ReviewCurrent treatment options in gastroenterology2016

Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy.

Galen Leung, Marianna Papademetriou, Shannon Chang, Francis Arena, Seymour Katz

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Galen LeungDivision of Gastroenterology, Department of Medicine, New York University School of Medicine, 550 1st Avenue, New York, NY, USA.
Marianna PapademetriouDivision of Gastroenterology, Department of Medicine, New York University School of Medicine, 550 1st Avenue, New York, NY, USA.
Shannon ChangDivision of Gastroenterology, Department of Medicine, New York University School of Medicine, 550 1st Avenue, New York, NY, USA.
Francis ArenaDivision of Hematology and Medical Oncology, Department of Medicine, New York University School of Medicine, New York, NY, USA.
Seymour KatzDivision of Gastroenterology, Department of Medicine, New York University School of Medicine, 550 1st Avenue, New York, NY, USA. seymourkatz.md@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementAs new and effective novel therapies in inflammatory bowel disease (IBD) become available, patients are living longer with advancing age and are at increased risk for malignancy. The management of IBD and malignancy involves multiple combinations of chemotherapy agents and IBD drugs, with the potential for interactions between these therapies. Interactions may either potentiate the effectiveness of drug class or exacerbate their common side effects. In this review article, we present a guide on studied interactions between IBD therapies and chemotherapy agents, specifically those of colorectal cancer, breast cancer, non-Hodgkin's lymphoma, and melanoma. The pharmacology and pharmocokinetics of each IBD drug will be discussed. Then, the IBD drug and chemotherapy interactions are summarized in table format. This guide will provide a quick reference to guide clinicians with this challenging management of two disease processes.

Indexed as

Anti-TNF-alpha inhibitorCancerChemotherapyInflammatory bowel diseaseMethotrexateThiopurine

Identifiers

PMID27709332

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.